Logotype for ICU Medical Inc

ICU Medical (ICUI) Q4 2009 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for ICU Medical Inc

Q4 2009 earnings summary

6 Nov, 2026

Executive summary

  • FY09 delivered record revenue of $231.5M and net income of $26.6M; diluted EPS was $1.77.

  • Growth in custom products, new products and direct sales offset lower Hospira sales, while the critical care asset purchase shifted sales responsibility to direct channels.

Financial highlights

  • Revenue rose to $231.5M from $204.7M in 2008; net sales were $231.0M.

  • Operating income increased 21% to $38.0M; net income was $26.6M versus $24.3M, with diluted EPS of $1.77 versus $1.67.

  • Q4 revenue was $69.8M, gross profit $31.4M, net income $7.4M and diluted EPS $0.50.

  • Operating cash flow reached a record $48.6M; cash, cash equivalents and investment securities were $108.1M at year-end.

Outlook and guidance

  • FY10 gross margin estimated at ~43%, versus 47% in FY09; SG&A estimated at 27%-28% of revenue, versus 30% in FY09.

  • FY10 capital expenditures estimated at $17M-$20M, including ~$10M to complete the Slovakia plant.

  • FY10 U.S. CLAVE growth expected to be modest; critical care sales expected to increase, and custom infusion and oncology sales expected to continue rising.

  • Existing cash, investments and anticipated operating cash flow expected to fund operations for the next 12 months.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from ICU Medical